Oct 22 2009, 10:43 AM EST
GEN News Highlights
Australia-based Genetic Technologies obtained exclusive distribution rights to Rosetta Genomics’ miRNA-based cancer tests—miRview™ mets, miRview™ squamous, and miRview™ meso—in Australia, New Zealand, and Singapore.
miRview mets is designed to accurately identify the primary tumor site in patients presenting with metastatic cancer and those with cancer of unknown primary. miRview squamous differentiates squamous from nonsquamous non-small-cell lung cancer. miRview meso uses miRNA specificity as biomarkers to differentiate mesothelioma from other lung carcinomas.
Rosetta’s deal with Genetic Technologies follows a September agreement with AXA Diagnostics for distribution of the same three tests in Italy.
♦♦♦
Related News
Rosetta's miRNA-Based Cancer Tests Break Into European Market through Distribution Deal with AXA (Sep. 8, 2009)
Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics (Aug. 10, 2009)
Prometheus Gains U.S. Rights to Rosetta's Cancer Tests (Apr. 13, 2009)
Rosetta Launches Second miRNA Diagnostic for Cancers of Unknown Primary (Dec. 22, 2008)
Rosetta Genomics to Provide miRNA-Based Cancer Diagnostic (Dec. 12, 2008)
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More GEN News Highlights
Listen
Save
Comment
View All